Search

Li-rich layered oxide (LLO) cathodes hold great promise for high-energy lithium-ion batteries, but suffer from rapid voltage and capacity degradation, and inferior rate capability. Besides, traditional synthesis approaches require long-time heat treatment (typically several hours) due to the sluggish kinetics, leading to high energy consumption and cost. Here, we introduce an innovative approach to address these challenges through ultrafast synthesis of cation/anion co-doped LLO with structural defects. By utilizing a rapid synthesis technique of nickel foil-based thermal shock, simultaneous doping of cation and anion species into the LLO structure with Li+/Ni2+ mixing defects is achieved in seconds. The ultrafast synthesis remarkably reduces the cost and energy consumption. Furthermore, this cation/anion co-doping and Li+/Ni2+ mixing defects significantly enhance lithium-ion transport and suppress the irreversible oxygen release and structural transformation, and demonstrate enhanced cycling stability with minimal voltage degradation over extended charge–discharge cycles and improved rate capability. Our findings offer a promising avenue to unlock the full potential and an effective synthesis approach of Li-rich layered oxide cathodes for advanced lithium-ion batteries. [ABSTRACT FROM AUTHOR]

Objective: Total hip arthroplasty (THA) effectively treats end‐stage hemophilic hip arthropathy. Given hemophilia's unique characteristics, perioperative bleeding remains a significant risk for patients undergoing THA. Tranexamic acid (TXA), an efficient antifibrinolytic agent, may benefit the outcomes of THA for patients with hemophilia (PWH). This study aims to explore the clinical efficacy of intra‐articular injection of TXA in treating perioperative bleeding in PWH and assess its additional clinical benefits. Methods: The retrospective study comprised data of PWH who received THA from January 2015 to December 2021 in the research center. A total of 59 individuals were included in the study, divided into a TXA group (n = 31) and a non‐TXA group (n = 28). We compared various parameters, including total blood loss (TBL), visible blood loss (VBL), occult blood loss (OBL), intraoperative coagulation factor VIII (FVIII) consumption, perioperative total FVIII consumption, hemoglobin (HB), erythrocyte sedimentation rate (ESR), C‐reactive protein (CRP), length of hospital stay, hospitalization costs, length of surgery, total protein, activated partial thromboplastin time (APTT), D‐dimer, rate of joint swelling, hip joint range of motion (ROM), visual analogue scale (VAS), and Harris hip joint function scale (HHS) between the two groups. Follow‐up assessments were conducted for up to 24 months. A Student's t test was utilized for the statistical analysis. Results: This study demonstrated that intra‐articular TXA effectively reduced TBL (1248.19 ± 439.88 mL, p < 0.001), VBL (490.32 ± 344.34 mL, p = 0.003), and OBL (757.87 ± 381.48 mL, p = 0.004) in PWH who underwent THA. TXA demonstrated effectiveness in reducing VAS scores on POD1, POD7, and POD14 and joint swelling rates on POD1, POD7, POD14, and at discharge (p < 0.05). Additionally, the TXA group achieved higher HHS ratings at all follow‐up time points (p < 0.05), showing superior hip joint mobility, lower postoperative inflammation levels, reduced factor VIII consumption during surgery, and less postoperative nutritional loss. No statistically significant differences were observed between the two groups in terms of hospital stay, hospitalization costs, surgery duration, and coagulation indicators. Conclusion: Intra‐articular injection of TXA reduces perioperative bleeding in PWH undergoing THA while also improving joint mobility, post‐operative rehabilitation, and quality of life. This may provide value for the future application of TXA in PWH. [ABSTRACT FROM AUTHOR]

Background: The aim was to evaluate the effect of beta‐blockers (BB) on the response of heart rate (HR) to 6‐min walk test (6MWT) in atrial fibrillation (AF) and whether the AF patients treated with BB have a similar HR response to 6MWT as the AF and sinus rhythm (SR) patients without BB treatment at the same resting HR level. Methods: The before–after study involving 74 AF patients was to evaluate the effect of BB treatment (pre‐BB and with BB). The comparison study included 74 BB‐treated AF patients (with BB), 74 matched AF patients without BB (no BB), and 74 SR patients. The percentage increase amplitude of HR (HR‐PIA) in 6MWT was calculated: [(the exercise HR − the resting HR)/(the resting HR)] × 100%. Results: The before–after study showed that BB treatment decreased the resting and mean exercise HR (98.6 ± 15.2 vs. 85.5 ± 11.2 bpm and 121.3 ± 17.3 vs. 109.0 ± 16.7 bpm) during 6MWT. The comparison study demonstrated that against the SR, the AF with BB and no BB groups have higher mean exercise HR‐PIA (28.2 ± 17.1% and 22.0 ± 9.6%, vs. 6.9 ± 3.7%) when their resting HR is similar. Moreover, the mean exercise HR‐PIA was also significantly higher in the with BB group than in the no BB group. Conclusion: In AF patients with relatively higher resting HR, BB treatment could decrease the resting and exercise HR during 6MWT. However, BB treatment could not effectively attenuate the exercise HR rise as compared with AF without BB treatment, even with similar resting HR levels. [ABSTRACT FROM AUTHOR]